Carvedilol, which is vasodilating (through α1B-AR blockage) in addition to its β-AR blockage, have metabolic effects that contribute to better outcomes in HF, compared with pure β-AR blockers [369,370,371,372,373,374,375]. The gene discussed is ADRB2; the disease is hydrops fetalis.